source
- Scribe Therapeutics targets $96 million IPO to fund PCSK9 gene-silencing programScribe Therapeutics, a Bay Area biotech focused on genetic medicines, filed with the SEC outlining plans for an initial public offering on Nasdaq. The company aims to sell 7.1 million shares at $1…
- Baxter alerts users to potential air bubble risk in Duo-Vent IV solution setsThe FDA’s Center for Devices and Radiological Health has issued an early alert about a possible high-risk issue with Baxter’s Duo-Vent intravenous solution sets. The devices may contain air bubbles…